Pharma News

Biovance Solutions, a UK based Company, leading provider of pharmacovigilance, regulatory, and pre-clinical research services, has signed a Memorandum of Understanding (MoU) with MIET (Meerut Institute of Engineering & Technology) to foster collaboration in the areas of Pharmacovigilance (PV), Regulatory Affairs, and Pre-Clinical Trial Services.

Novo Nordisk has launched legal action against US telehealth company Hims & Hers, accusing it of unlawfully marketing unapproved and potentially unsafe compounded versions of its bestselling GLP-1 medicines Wegovy® and Ozempic®.

Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).

Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.

Researchers have developed an innovative oxygen-boosted microneedle patch that significantly improves drug delivery and photodynamic therapy (PDT) for psoriasis, a chronic inflammatory skin disease that affects millions worldwide.

The study, published in Acta Pharmaceutica Sinica B, describes a dual-section microneedle (MN) patch designed to overcome two major challenges in psoriasis treatment: poor drug penetration through thickened skin and reduced efficacy of PDT caused by low oxygen levels in inflamed lesions.

Advances in soft and sustainable wearable bioelectronics are set to transform personal health monitoring and digital healthcare, according to a new Perspective article published in BIO Integration. Researchers highlight how skin-like wearable systems can continuously track health signals during daily life, moving care beyond occasional hospital visits.